MedDataX Logo

Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin

NCT ID: NCT01701180

Last Updated: 2014-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mounting evidence indicates that the intranasal administration of the neuropeptide oxytocin has prosocial effects. However, the neural substrates of these effects are still unclear. The investigators hypothesized that a single dose administration of oxytocin should increase empathogenic and affiliative responses and that these effects are mediated by an increased insula activity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxytocin

24 IU Oxytocin, intranasal application 45 min prior to the experiment

Group Type EXPERIMENTAL

Oxytocin

Intervention Type DRUG

24 IU; 3 puffs per nostril, each with 4 IU OXT

Placebo

Intranasal application, sodium chloride solution, 3 puffs per nostril

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxytocin

24 IU; 3 puffs per nostril, each with 4 IU OXT

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oxytocin: Syntocinon-Spray, Novartis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male volunteers
* In a heterosexual relationship

Exclusion Criteria

* Current or past psychiatric disease
* Current or past physical illness
* Psychoactive medication
* Tobacco smokers
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bonn

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rene Hurlemann

MSc MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

René Hurlemann, MD PhD M.Sc.

Role: PRINCIPAL_INVESTIGATOR

Department of Psychiatry University of Bonn

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Psychiatry, University of Bonn

Bonn, North Rhine-Westphalia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Related Links

Access external resources that provide additional context or updates about the study.

http://renehurlemann.squarespace.com/welcome/

NEMO research group

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OXT-151/12

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

OXT-151/12

Identifier Type: -

Identifier Source: org_study_id